Apolipoprotein E controls the risk and age at onset of Parkinson disease
Similarities between Alzheimer disease (AD) and Parkinson disease (PD) suggest a possible role for apolipoprotein E (APOE) in PD. Most previous studies seeking to establish such a link used case-control datasets and results have been inconsistent. To investigate APOE's role in PD using family-b...
Gespeichert in:
Veröffentlicht in: | Neurology 2004-06, Vol.62 (11), p.2005-2009 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2009 |
---|---|
container_issue | 11 |
container_start_page | 2005 |
container_title | Neurology |
container_volume | 62 |
creator | LI, Y. J HAUSER, M. A PAHWA, R STERN, M. B HINER, B. C JANKOVIC, J GOETZ, C. G SMALL, G. W MASTAGLIA, F HAINES, J. L PERICAK-VANCE, M. A VANCE, J. M SCOTT, W. K MARTIN, E. R BOOZE, M. W QIN, X. J WALTER, J. W NANCE, M. A HUBBLE, J. P KOLLER, W. C |
description | Similarities between Alzheimer disease (AD) and Parkinson disease (PD) suggest a possible role for apolipoprotein E (APOE) in PD. Most previous studies seeking to establish such a link used case-control datasets and results have been inconsistent.
To investigate APOE's role in PD using family-based association analyses.
APOE functional polymorphisms were genotyped for 658 PD affected families, including 282 multiplex and 376 singleton families. The pedigree disequilibrium test (PDT) and the genotype-PDT were used to test the risk effect of APOE. The Monks-Kaplan test was used to evaluate the effect of APOE on age at onset of PD.
APOE was significantly associated with risk of developing PD. Stratified analysis revealed that APOE was most strongly associated with families with a positive PD family history (global p = 0.003). Like AD, the APOE-4 allele increases disease risk while the APOE-3 allele decreases risk. We detected a positive association of APOE-3 (p = 0.019) and a negative association of APOE-4 (p = 0.015) with age at onset in PD.
The APOE-4 allele increases risk and decreases age at onset of PD, an association that may not be dependent upon cognitive impairment. |
doi_str_mv | 10.1212/01.WNL.0000128089.53030.AC |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71995767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71995767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-196ae0b77944f48c14f98c76dbbaf6e8ee225f5c1a5fff4375c22354bfe6fc83</originalsourceid><addsrcrecordid>eNpNkE1LAzEQhoMotlb_ggRBb7vmY_Ox3kqpVijqoaC3kE0nuna7qcn24L93tYU6h5nL884MD0JXlOSUUXZLaP76NM9JX5RpostccMJJPp4coSEVTGaSs7djNCSE6YxrpQfoLKXPHhdMladoQAXVhSRiiGbjTWjqTdjE0EHd4il2oe1iaBLuPgDHOq2wbZfYvgO2HQ5tgr57_GLjqm5TaPGyTmATnKMTb5sEF_s5Qov76WIyy-bPD4-T8TxzvBBdRktpgVRKlUXhC-1o4UvtlFxWlfUSNABjwgtHrfDeF1wJxxgXReVBeqf5CN3s1vYPf20hdWZdJwdNY1sI22QULUuhpOrBux3oYkgpgjebWK9t_DaUmF-NhlDTazQHjeZPoxlP-vDl_sq2WsPyEN1764HrPWCTs42PtnV1-sdpIZXW_AdsvHwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71995767</pqid></control><display><type>article</type><title>Apolipoprotein E controls the risk and age at onset of Parkinson disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>LI, Y. J ; HAUSER, M. A ; PAHWA, R ; STERN, M. B ; HINER, B. C ; JANKOVIC, J ; GOETZ, C. G ; SMALL, G. W ; MASTAGLIA, F ; HAINES, J. L ; PERICAK-VANCE, M. A ; VANCE, J. M ; SCOTT, W. K ; MARTIN, E. R ; BOOZE, M. W ; QIN, X. J ; WALTER, J. W ; NANCE, M. A ; HUBBLE, J. P ; KOLLER, W. C</creator><creatorcontrib>LI, Y. J ; HAUSER, M. A ; PAHWA, R ; STERN, M. B ; HINER, B. C ; JANKOVIC, J ; GOETZ, C. G ; SMALL, G. W ; MASTAGLIA, F ; HAINES, J. L ; PERICAK-VANCE, M. A ; VANCE, J. M ; SCOTT, W. K ; MARTIN, E. R ; BOOZE, M. W ; QIN, X. J ; WALTER, J. W ; NANCE, M. A ; HUBBLE, J. P ; KOLLER, W. C</creatorcontrib><description>Similarities between Alzheimer disease (AD) and Parkinson disease (PD) suggest a possible role for apolipoprotein E (APOE) in PD. Most previous studies seeking to establish such a link used case-control datasets and results have been inconsistent.
To investigate APOE's role in PD using family-based association analyses.
APOE functional polymorphisms were genotyped for 658 PD affected families, including 282 multiplex and 376 singleton families. The pedigree disequilibrium test (PDT) and the genotype-PDT were used to test the risk effect of APOE. The Monks-Kaplan test was used to evaluate the effect of APOE on age at onset of PD.
APOE was significantly associated with risk of developing PD. Stratified analysis revealed that APOE was most strongly associated with families with a positive PD family history (global p = 0.003). Like AD, the APOE-4 allele increases disease risk while the APOE-3 allele decreases risk. We detected a positive association of APOE-3 (p = 0.019) and a negative association of APOE-4 (p = 0.015) with age at onset in PD.
The APOE-4 allele increases risk and decreases age at onset of PD, an association that may not be dependent upon cognitive impairment.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/01.WNL.0000128089.53030.AC</identifier><identifier>PMID: 15184605</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Age of Onset ; Aged ; Alleles ; Apolipoprotein E3 ; Apolipoprotein E4 ; Apolipoproteins E - genetics ; Apolipoproteins E - physiology ; Australia - epidemiology ; Biological and medical sciences ; Cognition ; Dementia - epidemiology ; Dementia - genetics ; Female ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; Humans ; Male ; Medical sciences ; Middle Aged ; Neurology ; Neuropsychological Tests ; Parkinson Disease - epidemiology ; Parkinson Disease - genetics ; Parkinson Disease - psychology ; Pedigree ; Risk ; United States - epidemiology</subject><ispartof>Neurology, 2004-06, Vol.62 (11), p.2005-2009</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-196ae0b77944f48c14f98c76dbbaf6e8ee225f5c1a5fff4375c22354bfe6fc83</citedby><cites>FETCH-LOGICAL-c345t-196ae0b77944f48c14f98c76dbbaf6e8ee225f5c1a5fff4375c22354bfe6fc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15856788$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15184605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LI, Y. J</creatorcontrib><creatorcontrib>HAUSER, M. A</creatorcontrib><creatorcontrib>PAHWA, R</creatorcontrib><creatorcontrib>STERN, M. B</creatorcontrib><creatorcontrib>HINER, B. C</creatorcontrib><creatorcontrib>JANKOVIC, J</creatorcontrib><creatorcontrib>GOETZ, C. G</creatorcontrib><creatorcontrib>SMALL, G. W</creatorcontrib><creatorcontrib>MASTAGLIA, F</creatorcontrib><creatorcontrib>HAINES, J. L</creatorcontrib><creatorcontrib>PERICAK-VANCE, M. A</creatorcontrib><creatorcontrib>VANCE, J. M</creatorcontrib><creatorcontrib>SCOTT, W. K</creatorcontrib><creatorcontrib>MARTIN, E. R</creatorcontrib><creatorcontrib>BOOZE, M. W</creatorcontrib><creatorcontrib>QIN, X. J</creatorcontrib><creatorcontrib>WALTER, J. W</creatorcontrib><creatorcontrib>NANCE, M. A</creatorcontrib><creatorcontrib>HUBBLE, J. P</creatorcontrib><creatorcontrib>KOLLER, W. C</creatorcontrib><title>Apolipoprotein E controls the risk and age at onset of Parkinson disease</title><title>Neurology</title><addtitle>Neurology</addtitle><description>Similarities between Alzheimer disease (AD) and Parkinson disease (PD) suggest a possible role for apolipoprotein E (APOE) in PD. Most previous studies seeking to establish such a link used case-control datasets and results have been inconsistent.
To investigate APOE's role in PD using family-based association analyses.
APOE functional polymorphisms were genotyped for 658 PD affected families, including 282 multiplex and 376 singleton families. The pedigree disequilibrium test (PDT) and the genotype-PDT were used to test the risk effect of APOE. The Monks-Kaplan test was used to evaluate the effect of APOE on age at onset of PD.
APOE was significantly associated with risk of developing PD. Stratified analysis revealed that APOE was most strongly associated with families with a positive PD family history (global p = 0.003). Like AD, the APOE-4 allele increases disease risk while the APOE-3 allele decreases risk. We detected a positive association of APOE-3 (p = 0.019) and a negative association of APOE-4 (p = 0.015) with age at onset in PD.
The APOE-4 allele increases risk and decreases age at onset of PD, an association that may not be dependent upon cognitive impairment.</description><subject>Adult</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>Alleles</subject><subject>Apolipoprotein E3</subject><subject>Apolipoprotein E4</subject><subject>Apolipoproteins E - genetics</subject><subject>Apolipoproteins E - physiology</subject><subject>Australia - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Cognition</subject><subject>Dementia - epidemiology</subject><subject>Dementia - genetics</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>Parkinson Disease - epidemiology</subject><subject>Parkinson Disease - genetics</subject><subject>Parkinson Disease - psychology</subject><subject>Pedigree</subject><subject>Risk</subject><subject>United States - epidemiology</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1LAzEQhoMotlb_ggRBb7vmY_Ox3kqpVijqoaC3kE0nuna7qcn24L93tYU6h5nL884MD0JXlOSUUXZLaP76NM9JX5RpostccMJJPp4coSEVTGaSs7djNCSE6YxrpQfoLKXPHhdMladoQAXVhSRiiGbjTWjqTdjE0EHd4il2oe1iaBLuPgDHOq2wbZfYvgO2HQ5tgr57_GLjqm5TaPGyTmATnKMTb5sEF_s5Qov76WIyy-bPD4-T8TxzvBBdRktpgVRKlUXhC-1o4UvtlFxWlfUSNABjwgtHrfDeF1wJxxgXReVBeqf5CN3s1vYPf20hdWZdJwdNY1sI22QULUuhpOrBux3oYkgpgjebWK9t_DaUmF-NhlDTazQHjeZPoxlP-vDl_sq2WsPyEN1764HrPWCTs42PtnV1-sdpIZXW_AdsvHwA</recordid><startdate>20040608</startdate><enddate>20040608</enddate><creator>LI, Y. J</creator><creator>HAUSER, M. A</creator><creator>PAHWA, R</creator><creator>STERN, M. B</creator><creator>HINER, B. C</creator><creator>JANKOVIC, J</creator><creator>GOETZ, C. G</creator><creator>SMALL, G. W</creator><creator>MASTAGLIA, F</creator><creator>HAINES, J. L</creator><creator>PERICAK-VANCE, M. A</creator><creator>VANCE, J. M</creator><creator>SCOTT, W. K</creator><creator>MARTIN, E. R</creator><creator>BOOZE, M. W</creator><creator>QIN, X. J</creator><creator>WALTER, J. W</creator><creator>NANCE, M. A</creator><creator>HUBBLE, J. P</creator><creator>KOLLER, W. C</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040608</creationdate><title>Apolipoprotein E controls the risk and age at onset of Parkinson disease</title><author>LI, Y. J ; HAUSER, M. A ; PAHWA, R ; STERN, M. B ; HINER, B. C ; JANKOVIC, J ; GOETZ, C. G ; SMALL, G. W ; MASTAGLIA, F ; HAINES, J. L ; PERICAK-VANCE, M. A ; VANCE, J. M ; SCOTT, W. K ; MARTIN, E. R ; BOOZE, M. W ; QIN, X. J ; WALTER, J. W ; NANCE, M. A ; HUBBLE, J. P ; KOLLER, W. C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-196ae0b77944f48c14f98c76dbbaf6e8ee225f5c1a5fff4375c22354bfe6fc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>Alleles</topic><topic>Apolipoprotein E3</topic><topic>Apolipoprotein E4</topic><topic>Apolipoproteins E - genetics</topic><topic>Apolipoproteins E - physiology</topic><topic>Australia - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Cognition</topic><topic>Dementia - epidemiology</topic><topic>Dementia - genetics</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>Parkinson Disease - epidemiology</topic><topic>Parkinson Disease - genetics</topic><topic>Parkinson Disease - psychology</topic><topic>Pedigree</topic><topic>Risk</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LI, Y. J</creatorcontrib><creatorcontrib>HAUSER, M. A</creatorcontrib><creatorcontrib>PAHWA, R</creatorcontrib><creatorcontrib>STERN, M. B</creatorcontrib><creatorcontrib>HINER, B. C</creatorcontrib><creatorcontrib>JANKOVIC, J</creatorcontrib><creatorcontrib>GOETZ, C. G</creatorcontrib><creatorcontrib>SMALL, G. W</creatorcontrib><creatorcontrib>MASTAGLIA, F</creatorcontrib><creatorcontrib>HAINES, J. L</creatorcontrib><creatorcontrib>PERICAK-VANCE, M. A</creatorcontrib><creatorcontrib>VANCE, J. M</creatorcontrib><creatorcontrib>SCOTT, W. K</creatorcontrib><creatorcontrib>MARTIN, E. R</creatorcontrib><creatorcontrib>BOOZE, M. W</creatorcontrib><creatorcontrib>QIN, X. J</creatorcontrib><creatorcontrib>WALTER, J. W</creatorcontrib><creatorcontrib>NANCE, M. A</creatorcontrib><creatorcontrib>HUBBLE, J. P</creatorcontrib><creatorcontrib>KOLLER, W. C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LI, Y. J</au><au>HAUSER, M. A</au><au>PAHWA, R</au><au>STERN, M. B</au><au>HINER, B. C</au><au>JANKOVIC, J</au><au>GOETZ, C. G</au><au>SMALL, G. W</au><au>MASTAGLIA, F</au><au>HAINES, J. L</au><au>PERICAK-VANCE, M. A</au><au>VANCE, J. M</au><au>SCOTT, W. K</au><au>MARTIN, E. R</au><au>BOOZE, M. W</au><au>QIN, X. J</au><au>WALTER, J. W</au><au>NANCE, M. A</au><au>HUBBLE, J. P</au><au>KOLLER, W. C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apolipoprotein E controls the risk and age at onset of Parkinson disease</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2004-06-08</date><risdate>2004</risdate><volume>62</volume><issue>11</issue><spage>2005</spage><epage>2009</epage><pages>2005-2009</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>Similarities between Alzheimer disease (AD) and Parkinson disease (PD) suggest a possible role for apolipoprotein E (APOE) in PD. Most previous studies seeking to establish such a link used case-control datasets and results have been inconsistent.
To investigate APOE's role in PD using family-based association analyses.
APOE functional polymorphisms were genotyped for 658 PD affected families, including 282 multiplex and 376 singleton families. The pedigree disequilibrium test (PDT) and the genotype-PDT were used to test the risk effect of APOE. The Monks-Kaplan test was used to evaluate the effect of APOE on age at onset of PD.
APOE was significantly associated with risk of developing PD. Stratified analysis revealed that APOE was most strongly associated with families with a positive PD family history (global p = 0.003). Like AD, the APOE-4 allele increases disease risk while the APOE-3 allele decreases risk. We detected a positive association of APOE-3 (p = 0.019) and a negative association of APOE-4 (p = 0.015) with age at onset in PD.
The APOE-4 allele increases risk and decreases age at onset of PD, an association that may not be dependent upon cognitive impairment.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>15184605</pmid><doi>10.1212/01.WNL.0000128089.53030.AC</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3878 |
ispartof | Neurology, 2004-06, Vol.62 (11), p.2005-2009 |
issn | 0028-3878 1526-632X |
language | eng |
recordid | cdi_proquest_miscellaneous_71995767 |
source | MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection |
subjects | Adult Age of Onset Aged Alleles Apolipoprotein E3 Apolipoprotein E4 Apolipoproteins E - genetics Apolipoproteins E - physiology Australia - epidemiology Biological and medical sciences Cognition Dementia - epidemiology Dementia - genetics Female Gene Frequency Genetic Predisposition to Disease Genotype Humans Male Medical sciences Middle Aged Neurology Neuropsychological Tests Parkinson Disease - epidemiology Parkinson Disease - genetics Parkinson Disease - psychology Pedigree Risk United States - epidemiology |
title | Apolipoprotein E controls the risk and age at onset of Parkinson disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A33%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apolipoprotein%20E%20controls%20the%20risk%20and%20age%20at%20onset%20of%20Parkinson%20disease&rft.jtitle=Neurology&rft.au=LI,%20Y.%20J&rft.date=2004-06-08&rft.volume=62&rft.issue=11&rft.spage=2005&rft.epage=2009&rft.pages=2005-2009&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/01.WNL.0000128089.53030.AC&rft_dat=%3Cproquest_cross%3E71995767%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71995767&rft_id=info:pmid/15184605&rfr_iscdi=true |